Fisetin — Research Profile

Senescent cells are damaged cells that stop dividing but refuse to die. They accumulate with age and secrete inflammatory molecules (the SASP) that damage surrounding healthy tissue, drive chronic inflammation, and accelerate aging. Clearing these "zombie" cells with senolytics like fisetin has been shown to improve health and extend lifespan in animal models.

Both approaches are used. Daily low doses (100-500mg) provide ongoing antioxidant and anti-inflammatory benefits. Intermittent high-dose protocols (1-2g for 2 consecutive days monthly) mimic the senolytic protocols used in clinical trials. The optimal approach for humans is still being determined in ongoing Mayo Clinic trials.

Strawberries are the richest food source, containing about 160μg fisetin per gram. To reach a 500mg supplemental dose, you would need to eat approximately 3kg (6.6 lbs) of strawberries daily, which is impractical. Supplementation is necessary for therapeutic doses.

Fisetin is used as the free flavone (aglycone) in supplements, and the meaningful distinction is delivery rather than chemical form. A randomized crossover study in healthy adults found that a hybrid-hydrogel formulation produced substantially higher blood levels than the same dose of unformulated fisetin, confirming that absorption-enhanced preparations deliver more of the compound (id 10). No head-to-head trial has shown that one branded delivery system produces better health outcomes than another, so 'best' here means better absorbed, not proven more effective.

Fisetin's headline reputation as a senolytic and anti-aging agent rests almost entirely on preclinical evidence: in mice it cleared senescent cells and extended median and maximum lifespan, and in cell culture it selectively killed senescent human cells at low toxicity, but the human component of that landmark work was limited to tissue in a dish (id 11, id 1). Systematic reviews of neuroprotective, cartilage, and ischemia-reperfusion effects are likewise built on animal and in-vitro studies, not clinical outcomes (id 2). The only human benefit data so far are modest and indirect, such as reduced inflammatory adipokines and improved lipids when 200 mg/day was combined with exercise in obese men, so no anti-aging benefit is yet proven in people (id 8).

There is no established daily dose for fisetin because researchers use two very different regimens. Senolytic (clear-out) trials give a high intermittent dose of about 20 mg/kg/day for only 2-3 consecutive days per cycle, roughly 1,000-1,500 mg for a typical adult, then nothing for weeks (id 9). The one chronic-daily human trial used 200 mg/day for 12 weeks (id 8). Because these strategies come from small or ongoing studies and no consumer intake has been validated, treat any label dose as unsettled rather than a proven target.

Time of day has never been directly compared for fisetin, so there is no evidence-based 'best' hour. The more relevant factor is that fisetin is fat-soluble and poorly absorbed, so taking it with a meal containing fat is a reasonable way to aid uptake (id 10). Note that senolytic protocols deliberately dose it in short intermittent bursts rather than every day, which matters more than clock timing (id 9).

Fisetin has a low-toxicity profile in cell studies, where it selectively kills senescent cells while sparing healthy dividing cells (id 1). In the completed Mayo Clinic carpal-tunnel trial, which used short intermittent 100 mg courses, the reported events were minor, such as loose bowels, headaches, leg cramping, and increased pain, with no serious drug-related toxicity (FITCATS-NCT05416515). Because human trials remain small, brief, and intermittent, day-to-day side effects at continuous doses are not well characterized, and uncommon or delayed effects cannot be ruled out.

No human drug-interaction studies of fisetin exist, so guidance rests on laboratory data. A 2024 in-vitro review classifies fisetin as an intermediate inhibitor of the drug-metabolizing enzyme CYP3A4 (about half-maximal inhibition near 40 micromolar), meaning that in principle high-dose supplements could slow the clearance of medications broken down by CYP3A4 (Kondza-2024). Whether this occurs at realistic supplement doses in people is unknown, and other proposed interactions are unconfirmed, so if you take prescription medications, especially ones with a narrow safety margin, check with a clinician before adding fisetin.

Fisetin is marketed to healthy adults interested in longevity and cellular-aging support, but it is important to understand that this use is experimental and its human benefits are unproven (id 11). Current human trials are targeting specific groups, such as older adults, postmenopausal breast cancer survivors with reduced physical function, and metabolically unhealthy men, not the general population (id 9, id 8). Pregnant or breastfeeding people, anyone on blood thinners or CYP3A4-metabolized medications, and those with bleeding disorders should avoid it or seek medical advice first, given the lack of safety data in these groups.

There is no established onset timeline for fisetin in people, because almost all outcome data come from mouse and cell studies rather than human endpoints. Its senolytic (senescent-cell-clearing) activity was described in mice as a 'hit-and-run' effect from short, intermittent dosing rather than something you feel day to day, and the human trials mirror this by dosing only a few days per cycle (id 11, id 9). The one human trial reporting metabolic changes measured them after 12 weeks of daily 200 mg alongside exercise, so any benefit is a matter of weeks-to-months, not days (id 8).

Long-term daily safety has not been established: human fisetin trials have been short, and the senolytic trials deliberately use brief intermittent dosing rather than continuous daily intake (id 9). The longest daily human exposure with published data was 200 mg/day for 12 weeks in obese men, but that trial reported only efficacy outcomes and no formal tolerability or adverse-event data, so it cannot vouch for daily safety (id 8). The reassuring senolytic safety story comes from mice, where fisetin was given at 500 mg/kg in the diet or 100 mg/kg orally for 5 days without evident toxicity (id 11); there is no published non-human-primate data and no long-term human follow-up.

No tolerable upper limit or defined human toxic dose exists for fisetin. In cell studies it behaves as a low-toxicity flavone that selectively kills senescent endothelial cells while sparing healthy dividing cells (id 1), and in mice oral doses of 100 mg/kg for 5 days or 500 mg/kg in the diet were used without reported toxicity (id 11). In the completed Mayo Clinic carpal-tunnel trial, intermittent 100 mg dosing produced only minor complaints such as loose bowels, so gastrointestinal upset is the more likely problem at higher intakes than organ toxicity (FITCATS-NCT05416515); because human data remain limited, mega-dosing beyond studied amounts is not justified.

No human study has tested fisetin combined with other supplements for added benefit, so any pairing is theoretical. The one practical consideration is absorption: unformulated fisetin is poorly and erratically absorbed, which is why products pair it with fats, phospholipids, or specialized delivery matrices (id 10). If you take blood thinners or antiplatelet supplements such as fish oil, ginkgo, or high-dose vitamin E, be cautious, because fisetin has shown antiplatelet activity in laboratory models and combining could add to bleeding risk.

Fisetin's main weakness is bioavailability: plain fisetin powder is absorbed poorly and inconsistently, so an enhanced-absorption format (liposomal, phospholipid/hydrogel, or micronized) is worth prioritizing over a raw-powder capsule (id 10). Check that the label states the actual fisetin content in milligrams rather than only a strawberry-extract blend, since dietary sources contain very little. Because flavonoid supplements are unregulated for purity, choose a brand with third-party identity and contaminant testing.